Advertisement
Canada markets open in 38 minutes

  • S&P/TSX

    21,554.86
    -26.44 (-0.12%)
     

  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     

  • DOW

    39,150.33
    +15.53 (+0.04%)
     

  • CAD/USD

    0.7307
    +0.0004 (+0.05%)
     

  • CRUDE OIL

    80.75
    +0.02 (+0.02%)
     

  • Bitcoin CAD

    83,664.30
    -4,372.38 (-4.97%)
     

  • CMC Crypto 200

    1,265.14
    -44.58 (-3.40%)
     

  • GOLD FUTURES

    2,336.70
    +5.50 (+0.24%)
     

  • RUSSELL 2000

    2,022.03
    +4.64 (+0.23%)
     

  • 10-Yr Bond

    4.2670
    +0.0100 (+0.23%)
     

  • NASDAQ futures

    19,935.00
    -47.75 (-0.24%)
     

  • VOLATILITY

    13.82
    +0.62 (+4.69%)
     

  • FTSE

    8,273.28
    +35.56 (+0.43%)
     

  • NIKKEI 225

    38,804.65
    +208.18 (+0.54%)
     

  • CAD/EUR

    0.6806
    -0.0020 (-0.29%)
     
MARKETS LIVE BLOG:

STOCK FUTURES INCH UP AS HIGH-FLYING Q2 NEARS CLOSE

S&P 500 is up around 4.5% this quarter, while the Nasdaq has surged about 8%

Savara to Present at the Jefferies Global Healthcare Conference

Business Wire
·1 min read

LANGHORNE, Pa., May 29, 2024--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:00am PT/10:00am ET. A live webcast of the fireside chat will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529491002/en/

Contacts

Savara Inc. IR & PR
Anne Erickson
anne.erickson@savarapharma.com
(512) 851-1366